- Home >
- Clinicals Trials >
- CA-4948-101
Lymphoma
CA-4948-101
An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Relapsed or Refractory Primary Central Nervous System Lymphom.
- Open at Saint-Cloud since : 22/03/2024
- Target : Adult
- Phase : Phase II
Trial description
To determine the safety and tolerability, dose-limiting substances (TLD), maximum tolerated dose (MTD), and recommended phase 2 dose (DRP2) of CA-4948 administered orally as monotherapy and in combination with ibrutinib.
Url of the trialMain investigator
